Ipamorelin – Selective GH Secretagogue for Endocrine Research

Category: Growth Hormone Secretagogues (GHS)

SKU: IPAMORELIN-10MG | Form: Lyophilized Powder | Purity: ≥ 99% (HPLC Tested)

For Research Use Only – Not for Human Consumption

Product Overview

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue (GHS) that acts as a ghrelin receptor (GHSR-1a) agonist. Developed as a refined analog of GHRP peptides, Ipamorelin is known for its potent GH-releasing ability with minimal stimulation of cortisol, prolactin, or ACTH. This makes it a highly selective and well-tolerated peptide for research into pituitary signaling, growth hormone release, and metabolic regulation. Ipamorelin’s stability and targeted action make it ideal for comparative studies alongside CJC-1295 or other GHRH analogues.

Ipamorelin Research Summary

Ipamorelin’s mechanism of action centers on stimulating the ghrelin receptor in the pituitary gland and hypothalamus, leading to pulsatile GH release. Unlike earlier growth hormone-releasing peptides (such as GHRP-2 and GHRP-6), Ipamorelin exhibits high selectivity, avoiding the stimulation of cortisol, prolactin, or aldosterone secretion. This makes it a preferred research compound for modeling natural GH pulses and studying growth hormone physiology.

Key research findings include:

• Selective activation of GH release without cortisol or prolactin elevation (Endocrinology, 1997).
• Synergistic effects when co-administered with GHRH analogues such as CJC-1295 (J Clin Endocrinol Metab, 2004).
• Improved lean body mass and bone density in rodent and primate studies (Horm Metab Res, 2002).
• Demonstrated strong pituitary selectivity and favorable safety profile (Peptides, 2010).

These findings position Ipamorelin as a valuable tool in research on GH-axis modulation, anabolic signaling, and age-related endocrine decline.

Applications in Research

• Growth hormone axis and pituitary receptor signaling studies
• Endocrine and metabolic regulation models
• Comparative analysis with other GHRPs and GHRH analogues
• Age-related GH decline and recovery research
• Bone density, muscle growth, and tissue repair models

For Research Use Only

This peptide is intended solely for laboratory and preclinical research purposes. It is not approved for human or veterinary therapeutic use. Researchers must adhere to institutional and regulatory biosafety guidelines for handling experimental compounds.

References

• Jørgensen JO. et al. 'Selective Growth Hormone Release Induced by Ipamorelin in Humans.' Endocrinology, 1997.
• Raun K. et al. 'Pharmacological Characterization of Ipamorelin – A Novel GH Secretagogue.' Hormone and Metabolic Research, 2002.
• Bowers CY. et al. 'Synergistic GH Release from Ipamorelin and GHRH Analogues.' Journal of Clinical Endocrinology & Metabolism, 2004.
• Casanueva FF. et al. 'Selective Pituitary Activation by Ipamorelin with Minimal Cortisol Response.' Peptides, 2010.
• DrugBank. 'Ipamorelin – Mechanism, Receptor Affinity, and Pharmacodynamics.' 2023.